Advaxis Announces First Patient Treated in Phase 1/2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

PRINCETON, N.J., March 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc.  (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in a Phase 1/2 clinical trial evaluating higher doses and repeat cycles of ADXS-HPV (ADXS11-001), an investigational Lm -LLO immunotherapy , for the treatment of patients with recurrent cervical cancer.

The interventional, open-label, non-randomized dose-escalation study is designed to evaluate the safety, efficacy and immunological effect of ADXS-HPV administered at doses up to 1 x 10 10 colony forming units (CFU) in repeat cycles of treatment in approximately 25 women with cervical cancer whose disease recurred after receiving one prior cytotoxic treatment regimen. Preclinical evidence with ADXS-HPV supports the potential for a dose-response relationship and warrants investigation beyond the 1 x 10 9 CFU 3 dose/cycle administration that has been studied with manageable safety to date. Further information about the Phase 1/2 study can be found on ClinicalTrials.gov , using Identifier NCT02164461.

Sharad Ghamande, M.D., Director of Gynecology Oncology Cancer Center, Georgia Reagents University Cancer Center, and principal investigator for the study, commented, "Recurrent cervical cancer is a fatal disease that has been resistant to most treatments, with a one-year survival rate of approximately 10-15%. Survival data from the Phase 2 studies with a single cycle of ADXS-HPV at a lower dose in this patient population was encouraging, and we hope that we can improve clinical outcomes by using a higher dose and repeat cycles of treatment."

In a completed Phase 2 study in 110 women with recurrent cervical cancer, one cycle (3 doses) of ADXS-HPV, at a dose of 1x10 9 CFU given as a monotherapy or in combination with chemotherapy, was shown to have a manageable safety profile with a 32% one-year survival rate (n=35/109 randomized treated patients alive at 12 months) and a 16% tumor response rate (n=11/69 response-evaluable patients). Additionally, the Gynecologic Oncology Group (GOG), now part of NRG Oncology, is conducting a single-arm 2-stage study ( ClinicalTrials.gov , using Identifier NCT01264460) with ADXS-HPV in patients with recurrent cervical cancer. The first stage of the study met the predetermined safety and efficacy criteria of >/=20% of treated patients surviving 12 months and is now enrolling patients into the second stage of the study. 

Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, stated, "Initiation of this Phase 1/2 clinical trial is a significant advancement of our ADXS-HPV development program in that this study is specifically designed to evaluate the potential benefits of treating patients at higher and repeated dosage cycles, which we believe could represent a key differentiator of, and competitive advantage for, ADXS-HPV, as well as our broader Lm -LLO immunotherapy platform among other investigational therapies. Importantly, we are not aware of any other Lm technology that has demonstrated or has the ability to dose safely and effectively at 1 x 10 10 CFU. Our hope is that this study will build upon the success of our recently completed and ongoing Phase 2 studies and drive our ADXS-HPV clinical development program forward if higher and repeat dosage regimens of ADXS-HPV offer improved treatment outcomes for these difficult-to-treat cervical cancer patients."

About Cervical Cancer

Cervical cancer is the fourth most common cancer and the most common cause of mortality in women worldwide. Approximately 528,000 new cases are reported annually and an estimated 266,000 deaths from cervical cancer are caused by the human papilloma virus (HPV) worldwide every year according to the World Health Organization / ICO Information Centre on Human Papillomavirus and Related Disease Report 2014. It is estimated that approximately 12,500 women a year are diagnosed with cervical cancer in the United States and approximately 4,000 a year will succumb to the disease. Locally advanced cervical cancer affects approximately 36% of patients at diagnosis (~4,500 in the US alone).

About ADXS-HPV

ADXS-HPV is Advaxis's lead immunotherapy product candidate for the treatment of HPV-associated cancers. It is currently under investigation in three HPV-associated cancers: invasive cervical cancer, head and neck cancer, and anal cancer. In cervical cancer, a recently completed Phase 2 study of ADXS-HPV demonstrated improved survival and a manageable safety profile alone or in combination with chemotherapy, which warrants further development of the molecule. Clinical trials in head and neck cancer and in anal cancer are ongoing. The U.S. Food and Drug Administration granted an orphan drug designation for ADXS-HPV for HPV-associated Stage II-IV cervical cancer, head and neck cancer, and for anal cancer.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor KEYTRUDA ® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.  Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 302

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Energy: Upgrading America's Aging Power Grid

Updated Category News Views 219

The Energy Conundrum Let’s face it, folks, the electric grid we’re using is like a beat-up old car—driving it won’t get any easier unless we pour in some cash and elbow grease. We all know increasing demand for power is putting the squeeze on the infrastructure, and everybody from policymakers to average homeowners is feeling the pinch. Do a little research (or...

Continue Reading
Cove Capital Investments Boosts Annual Distribution Rates Again

Updated Category News Views 69

Cove Capital Investments Announces Distribution Rate Increase The recent announcement regarding the increase in distribution rates by Cove Capital Investments highlights the success of its unique value-add strategy. This strategy is elaborated in the Private Placement Memorandum when the multifamily offering was made available to accredited investors. Performance of Cove...

Continue Reading
Broadcom Surges in After-Hours Trading on Stellar Earnings

Updated Category News Views 268

Broadcom Inc Reports Strong Earnings Broadcom Inc (NASDAQ: AVGO) experienced a remarkable 12.82% increase in its shares during after-hours trading after unveiling its first-quarter results. This rally followed a 6.33% decline during the regular trading hours, which was part of a larger trend of selloffs in the artificial intelligence (AI) chip market. Significant...

Continue Reading
Recent Downgrades: Analysts Weigh In on Key Stocks

Updated Category News Views 162

Analysts' Outlook on Key Stocks Recent changes from top Wall Street analysts revealed a shift in outlook on several prominent companies. Their evaluations often impact market trends and investor sentiment towards various stocks. Invivyd Inc Downgraded D. Boral Capital's Jason Kolbert downgraded the rating for Invivyd Inc (NASDAQ: IVVD) from Buy to Hold. On the trading...

Continue Reading
Innovative Grip Module Redefines Firearm Handling Experience

Updated Category News Views 299

Revolutionizing Firearm Grip with Innovative Design In the realm of firearm accessories, innovation often leads to transformative user experiences. One such breakthrough comes in the form of the 2911 Grip Module. This specially designed grip module addresses the common issues faced by firearm enthusiasts, offering a solution that enhances both comfort and usability. What...

Continue Reading